BVS
Bioventus Inc.NASDAQHealthcare$8.97-1.97%ClosedMarket Cap: $604.3M
As of 2026-04-06
Valuation
P/E (TTM)
26.58
PEG
0.16
P/B
3.26
P/S
1.07
EV/EBITDA
8.22
DCF Value
$-2.29
FCF Yield
11.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
67.3%
Operating Margin
10.0%
Net Margin
4.0%
ROE
13.8%
ROA
3.3%
ROIC
10.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $157.9M | 66.2% | $21.7M | $14.8M | $0.21 | — |
| FY 2025 | $568.1M | 67.3% | $58.5M | $22.7M | $0.33 | — |
| Q3 2025 | $138.7M | 67.0% | $12.1M | $3.2M | $0.05 | — |
| Q2 2025 | $147.7M | 69.1% | $18.4M | $7.5M | $0.11 | — |
| Q1 2025 | $123.9M | 67.0% | $4.9M | $-2.6M | $-0.04 | — |
| Q4 2024 | $153.6M | 66.8% | $8.0M | $-156.0K | $-0.00 | — |
| FY 2024 | $573.3M | 67.7% | $-12.0M | $-33.5M | $-0.52 | — |
| Q3 2024 | $139.0M | 67.3% | $4.1M | $-4.8M | $-0.07 | — |
| Q2 2024 | $151.2M | 68.5% | $-31.5M | $-25.7M | $-0.37 | — |
| Q1 2024 | $129.5M | 68.3% | $4.9M | $-4.9M | $-0.08 | — |
| Q4 2023 | $135.4M | 63.7% | $1.2M | $-6.1M | $-0.10 | — |
| FY 2023 | $512.3M | 64.1% | $-81.7M | $-156.2M | $-2.49 | — |